Franzin Martina, Di Lenardo Rebecca, Ruoso Rachele, Addobbati Riccardo
Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Via dell'Istria 65/1, 34137 Trieste, Italy.
Pharmaceutics. 2025 Mar 5;17(3):334. doi: 10.3390/pharmaceutics17030334.
: Cannabis oil titration consists of quantification of the acidic precursors tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) and their decarboxylated products, the active neutral cannabinoids delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and is recommended to ensure galenic preparation quality through gas and liquid chromatography coupled with mass spectrometry (GC-MS; LC-MS). Analyses by LC-MS and GC-MS involving derivatization allow for detection of acidic and neutral cannabinoids; on the contrary, GC-MS without derivatization determines only neutral cannabinoids due to high temperature-decarboxylation occurring in the injection system. However, it is not clear if decarboxylation is complete. : Different GC-MS methods with (BSTFA: TMCS and pyridine; incubation at 60 °C for 25 min) or without derivatization and an LC-MS method were developed for cannabinoid quantification. The total Δ9-THC and CBD yield of recovery were compared between the methods by testing laboratory samples with known concentrations of THCA and CBDA (total Δ9-THC and CBD: 175-351-702 ng/mL) and real cannabis oil samples (n = 6). : The total Δ9-THC and CBD yield of recovery were determined using LC-MS and GC-MS with derivatization, but not using GC-MS without derivatization (decarboxylation conversion rate of about 50-60%). No high deviation (<10%) in the total neutral cannabinoid concentrations in real cannabis oil samples was noticed, probably due to the low content of acidic forms in the original galenic preparation. : This study raised awareness about the potential underestimation of the total Δ9-THC and CBD content in cannabis oils when quantification is performed by GC-MS without derivatization. The advice for pharmacists is to perform complete decarboxylation to convert all acidic precursors in neutral cannabinoids.
大麻油滴定包括对酸性前体四氢大麻酚酸(THCA)和大麻二酚酸(CBDA)及其脱羧产物、活性中性大麻素Δ9-四氢大麻酚(Δ9-THC)和大麻二酚(CBD)进行定量,建议通过气相色谱-质谱联用(GC-MS)和液相色谱-质谱联用(LC-MS)来确保药剂制剂质量。涉及衍生化的LC-MS和GC-MS分析可检测酸性和中性大麻素;相反,未进行衍生化的GC-MS由于进样系统中发生高温脱羧反应,只能测定中性大麻素。然而,脱羧反应是否完全尚不清楚。:开发了不同的带有(BSTFA:TMCS和吡啶;60℃孵育25分钟)或不带有衍生化的GC-MS方法以及一种LC-MS方法用于大麻素定量。通过测试已知THCA和CBDA浓度(总Δ9-THC和CBD:175-351-702 ng/mL)的实验室样品和实际大麻油样品(n = 6),比较了这些方法之间总Δ9-THC和CBD的回收率。:使用带有衍生化的LC-MS和GC-MS测定了总Δ9-THC和CBD的回收率,但未使用未衍生化的GC-MS(脱羧转化率约为50-60%)。实际大麻油样品中总中性大麻素浓度未发现高偏差(<10%),这可能是由于原始药剂制剂中酸性形式的含量较低。:这项研究提高了人们对未进行衍生化的GC-MS进行定量时大麻油中总Δ9-THC和CBD含量可能被低估的认识。给药剂师的建议是进行完全脱羧,将所有酸性前体转化为中性大麻素。